NEW YORK (GenomeWeb News) – Thomson Reuters today said it and Orion Bionetworks are collaborating to elucidate the biological underpinnings of multiple sclerosis.

The collaboration also seeks to develop new therapies by generating predictive models of patient stratification and drug targets. Together, Thomson Reuters and Orion will combine their expertise and assets to "integrate and interpret clinical, molecular, imaging, and real-world patient data to develop new predictive models for" MS, Thomson Reuters said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.